

SUBSTITUTE SHEET (RULE 26)

USA

MD 20894,

National

09/214851

ogenası. Lespine

Human cytochrome P450 7215 bp HSU22027

(CYP2A6V2) DNA

22-0CT-1995

gene, complete cds PRI

> g1008461 U22027 DEFINITION ACCESSION

human. KEYWORDS SOURCE

Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Homo sapiens ORGANISM

Vertebrata; Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 7215) REFERENCE

Fernandez-Salguero, P., Hoffman, S.M., Cholerton, S., Mohrenweiser, H., Pelkonen, O., Huang, J.D., Evans, W.E.,

2/59

the

Raunio, H., Rautio, A., Idle, J.R. et,al.

A genetic polymorphism in coumarin 7-hydrozylation: sequence of human CYP2A genes and identification of variant CYP2A6 alleles (3), 651-660 (1995) Am. J. Hum. Genet. 57

JOURNAL

2 (bases 1 to 7215) 95397851 MEDLINE REFERENCE

Fernandez-Salguero, P. Direct Submission AUTHORS

Institutes of Health, 9000 Rockville Pike, Bethesda, Submitted (01-MAR-1995) Pedro Fernandez-Salguero, JOURNAL TITLE

source FEATURES

Location/Qualifiers

sapiens" /organism="Homo

FIG.2A

LOCUS

AUTHORS

FIG.2A CONT.

<u>⊢</u>
CO
.2A
FIG

							1627
/gene=CYP2A6V2: /number=3	/499/ /gene=CYP2A6V2: /number=4	32073383 /gene=CYP2A6V2:	/number=5 42564398 /gene=CYP2A6V2:	/number=6 48735060 /gene=CYP2A6V2:	/number=/ 55775718 /gene=CYP2A6V2:	/number=8 63086489 /gene=CYP2A6V2:	/number=9 64906744 1646 a 2196 c 1746 g
	exon	exon	exon	exon	exon	exon	3'UTR SE COUNT

FIG.2A CONT. BASE COUNT

							•											•				
gatggcagtg	tctgggcatc	ctgggctgct	aaactccaca	ggaatecee	cacagecaca	accccagat	caagtgctcc	ctcctaaatc	ccctctctg	ctaggcagga	agccaaagtc	tctatcatcc	gcctgactgt	ctccqqqacc	tatacaactc	tacctaqttg	aataqaatti	chahaaac			tannathada	
caatgaagaa		ggacccagtg	ctcctcccag	ccatatgcct	cccctaaatg	ctcccctgga	atccaaagcc	ctgttgcccc	gtctggaggc	gtgtcccaag	ttatgtaatc	gccgtcacca	ttactagect	gadagetae	aradadrada	acagagaaga	antritadda	agiciciagga agotonia	ageneeriga	gyccccaccc	grgagera atgapata	yryyacarya
characteda		atcagcccct	rhacacactc	actitoaadt	caacadaada	ttagatteet	cagaccccaa	tacagettat	cacagattta	cttgctggct	aatqaqqtaa	aaccaccca	trtatacc		yaayaycaay gaagataac	gcayctgaac	999cgccc9	tgiggaccay	tgggatgtcc	cccddcdcca		grggrgrgr
		artaaatraa	getadaeeda	yeryyyerey Faceocoa	cayccccyag	gcaceced	rteteactet	recteautte	cctdaaqtac	cttatcctcc	radagataa	tataaaddca	cacadaggea	cayyyarycz	ggcagcagag	gaaactact	acaggggagau	ggttgaccag	gacaggatct	cacatgacat	cacccacctc	ccggcgggtc
		ggcagccacc	tetygycaaa	ggagaacycc	rgggreree	CCLLddCCCL	tradatara	してはなりなららられ	caccecaaa	cygcacccc		-				ccttcattg		tgtggcaggg	gcatcagaaa	agcatcccag	taaccactcc	acttgggggcc
	cct		aagagacagc	gggctttctg	cccacagccc	ttcctgagac	ctttgtctta	ccgcacaacr	cctatycaaa	cacageeery	Licayoryco	trcarggray	catccctct	ctctaccacc	gatggtcttg	caccccattg	cctcatgaag	gctggggctt	tggagtťtca	ctgggtgcga	gttctccctc	ttcaccattc
1 510		19		81	241	301	361	421	481	541	201	. 99	721	781	8.11	901	961	1021	1081	1141	1201	1261

FIG.2A CONT.

accgctttga ctaggaatct tccagttcac ttaccaaaac gttctgcctg tggcgctggg ctctgagttg aggggaccc atccaatgga ctgggtaata tectgegett agcgcatcca cttaagaatc cccacctcc tgggtttctg taggatgcca ctcttccttc atcccacct ttctgggctt gagagtcccc teceteacet ccttattctc caccttcgac cacgaaggtc gtctttgggg gtgaaggccc ctggccgtac gccaagcagc ggcatcgagg cacggtgagc acccgcgcgc ccctggagtc ctcctcagac gccaatatcg ccctcttagc tccagctcag atctcactac cccactgccc tgcggacgcg tectetgtet gtaacagtct ctccatctct gcgagcaagc ggcaggtgga gaggataagg tccatgtgta tgccccacct gcgcatgatg agcccggccc acccggaggc cagetecatt gcacttccag aattctgact atctctctgt cggggagcgc gggcaagcga ccggagcacg aggacgagga tctcaattct aactctctgc atctccccat tecectetet gtctttgagg tgcctctctc ccatctcctg ttggggcctc agcgggcgag ggggaaggtg ctgacaactg aaaggcgccc taatggttgc ccaatgtcat tgtcactgtt gaaaacaccc tgcctcctgg ctcccgacat tegaggeeat ctcaatatta ctccacccag tctttctctc agctatgtgc tattcagcaa acttcggggt tctccctaca teceetetet tcttcaggct gattectece gtctacatga cggatccctt tgcccaagag cctgactctc gaggetetgg tggaccagge tgaggagtte aaagagttcc acggggcagg caaccccctt cgcacagtct ggcttcctca aacaaggccc aatgccgtga acctgaggg gcaggagaag ctaggtgggg ctcatctctc tacttccaca agaggatgtc tccatcactc ctaggcgtgg ctgtttctat ctgggtctct aaggctatgg cagccttctc tecetececa gccctgtcct tctcactgga gtctcctct gtcaacctcc actctctccc cttcctgagc ctataaggac acctgatcga ggaggagtcg gagtgcgggg gggatgggga aatttggctc tgccatcgcc gtgtggagct gggttattcc atcctctgcc qtctccagcg ttaccaqcc ctctgggttt cagaccctct tcacaccaag agtctggtct tcagtgttcc tgggtcttca 2401 2461 2101 2161 2281 2341 581 981 2041 921 801 861 561 681 741

FIG.2A CONT.

qtcagcaagg gagtcagggc aagggctggt gtctgggtga gtgagcctgc gattgcttga taagaaaaaa gaccagcctu catggtggcg ctgtaatccc attcaaatta atgaaacacc ttcatagcca ttcattgact atgcaaagcc tcagttcctt tgtccttccc gctcccaaa ggcacgtgtt ttcttgaata gattagttcc agacccgggt ccccggacag cggacagatg cccacgggac ttgcactcca caagtcagta ctgcggggag acacaggccc Egggtgccgt ggctaacagc aggagttcga attagttggg taaaaagtaa gaggctggag qctggaggac tgcctttaac ccgtgacagc atgagatgtt ctcttcggtg teccacegee aaactttaga gagtggaacc cacaacagat tacccaggtc ageteagete teteaecetg tgataattga gcaacgccag acctgaggtc aaatccaaaa gatcacggca atcacttgtt tcaggaggct ttagcaagac tgctgcaagg atcccaattc ccagcagcca caggcagatg agctcctgcc cctaaccacc ggagaccaga agatgctccc ttcccctacc gggggaaggg ggcccaaat caaattggca accgggatag cggaaaccct gggtacctaa ccttcctgt ctccagctac cctgtgcaac acagctaagt agcattgggg gggagtgggg aaaaaaatta gaggtacacc cacaattggc aatgagccaa caggtggatc tctctactaa cattcccatc ccccagctct gcctttcagt cgcacgctgg gcataccete aatttctaac ccgatttggg ctccagggac ccctgtgtca gagaaggaag cagaggttgc gcatgtgcag tggcgtccgg tcaaaccccg aaaaaagctg gaggccgagg gcagcaacag gcacaaccag taataatcct aaacaaatcc ctctctgcaa aaatcagtct ctctgaaata ccgcatgcag acttaccggt acagagectg ctggcaggat aaatcagtcc atcccctgct acceteatea taacgaaggt aggcagaggg agcactttgg gccaacatgg cgaagggggg cagaatgagg atggtcatgc gctcaggagt aaaaaacaaa ccttgctatg ttcccatcct cctttctcat tttaacacc tatccggccc tgccaggacc agaaggtgga cccatcccca tggttgtcca cggcaaattg tgtcccctca 3661 3361 3241 3481 3121 3181 3241 3301 541 3601 3061 3001

FIG.2A CONT.

greataggga tggaccccat gtctcccaaa acacatguec trecaettag accaagtttc cacattcccc aaccggcagc gagatccaaa gggactccag ctgtcccact ccaccccatt gggtgatgtc cccaagccca trectecty tgeeteect gagtctcatt ccagaccete accetgagae ctgctcatga cttcaggagg ttgaacctct cttggggtcc aacccctaga tettgeecea ccagactacg tttctagacc cgttccacct ggagaatcaa teggeettt aqtgatccac caaaaaggac caatgcgaat ggcatttcat gatacctaaa gatcggcaag tcacttctqt ggcatcagct agtetggtag gatetaggge ecetettete eaceetgegg gtggagggcc agatcccggg ctgtgtagat ccatggggtg cccctctcc tggcttctta gatgagcacg tagaaggaca aacagaagcc.ccctttccat ccccacccc cattagaagc ccaccacatc ctttgtgtca acatggaggc cccgcagagt ttgacagagt cataggcgga gagacccta gattggtcag ttaacaggat cctactccaa tcagctggta atcccctaag ccctgcacta gggacggaa cacctgtccc tgtcctaaag agaacctgat agactcgagt agtggaagat tctccagact acttccccaa aactcctgcc atcccaccca catgaggaga aagatgccct atgagtttgg gtgctatccg acttccgtct ccaccgggtc ttcctgctct tgtctgcact tgaacctaag ggagtgaggt agggcaacat ttctacttga gtcagcacca aaggctggag gcaatgtccc ggattgcgct cagaaatctc aggtccccca gtcctgcatc cctccctaag tgtccccagc gtcaaaaaag tatcttaaga agccaaggtc cgtgatcccc atattgaaaa actgcccgtt cacaacctgg tgaatgctct ggactatcat ggaccgggcc gtccagagac ttcgactggt ggtggagggt gagggtgctg cccattggtc aggtcaagca caccgagacg caacacggag ccaaacttcc ccctctctg ccctcaatca acactcctga trgcctatcc ccaagtttga gatttggaga gggatttctt tgttctgtta crccrcccc agcacccaga aaattcccc agatattaaa ctgagtgccc gtgattctgg tggtgccctg agaagaaccc tcattgcagg gtgacttgct aagagaggtc tcctagagcg cctcttgacc 4801 4681 4741 4621 4861 5041 4501 4441 4381

FIG.2A CONT

ggcggaaagg aagagtagta gagetteetg gaaagggcag cttctcttc ggacattgac aggetecete cagetggagg ccdcctctcc gttcttatct accccatctt tcagaggcgg taactaccaa tcccagggca cgtgatgctt gccctgtgt aggtccccaa ggggcaggat ggctcagttc ttatgctatg gagggtcaag actacaccat cggggccagg gggagagccg tccacccctc gaatggagct agtcacctaa gcatcgatca catacccctt atatttggga gcctagtatt gatactccct ctagggtcac cctcctcag tcccctcca gtttaagaag caggcttact tectectece caggttcttc agaggaagga aacccttaca ggaagaag aaacagaagc aagtcctccc atcccacgaa gctaagactg acagcaggtc tggacacctg gggcttcacc ggcctggcca gtctggtggg atttatttcc tgaggtcaag cttcctccct aaggaaacat agaagggca tgagagacct tgtttggtgc ctgccgtgta gccaccaggt ccccaaggt gcaccctagt acatacacct gaggggcgca cactgagagt cttccgcctc ctttgccacg gccggtgaag atattccacc tttcggagaa ctaccgtcga agaatcagag agatgacggc cctcccattg tcaaggaaac ggcaaaagga ggctccgtgc gttcccctct cagagatgtg aaccttctat cctcaccggg ccgcctcatc ttcctgggtg aagagaccac aacacgtggg cgagggctgt gggcttggga gtggctagag agctgggatg tttgggtcac tcagggccat ggcgaggctg agcggaactg tcatgcagaa ggatcttaaa cccttaccca tgttagcaat cctgtgccca cctaaaaagg tececageae ctccatcagt aaggccagag tgccacttcc atcccccaac ccctatgttg ggtgcttccg cctcaggaa traccaccg gtgtcccca ggccaagacc aaggggcgtg cccgctgag tiggicatet ttaaagtete teggtactgg gggaaaacca cttcagcatc ggggaaggg ggcaagttcc gcacccagta gggacttcaa ttgtgccctt cttcctgttt tagaagtgtt gcaggggcct ttcccatgcc actctcaaca 6241 6181 6301 6361 6061 5821 6001 5761 5641 5701

FIG.2A CONT.

ctgcacacat gcccacactc tgcttgctac cagataaggc acatgactgg acatacaggg aaaagcacc taagtgccca ctgtccgggg ctettattte etgageaegt acceeegtgt caecttigtt caaaaaceat ggcgttcatg cccattttac ctgaacatcc tcacaaaaca acagattctt cagcccaggg acacaacgag atcacatggc cctgccttca gactacccgg gtgtaatctg agccttctag cacaaaaccc ccttcgaagg agaaagttgt ctctgatgtc gggtggttgc ctgtgcccat ttagtataga aacatgctgt cattcagagt gagacctggg cctaatttgc acgtgacaaa actgaggctt gaaaatctgc gaacacagat tattcctcac gcaaaacagt aacaa gagttcccca tcacctactc cactgtagcċ tcagtccatt ataatagcag tgcacgctca 6781 6841 7021 6901 6961

09/214851

29-MAY-1992 PRI RNA 1415 bp HSP452B6

FOR CYTOCHROME P-450IIVB6 Human MRNA DEFINITION SUOO,

X13494

g35206 ACCESSION KEYWORDS

Cytochrome; cytochrome P450IIB6.

human. SOURCE

Primates; Catarrhini; Hominidae; Homo. Eukaryotae; mitochondrial eukaryotes; Metazoa; Chordata; Eutheria; Homo sapiens Vertebrata; ORGANISM

to 1415) 1 (bases 1 REFERENCE

Direct Submission Miles, J.S. AUTHORS TITLE

Submitted (10-NOV-1988) Miles J.S., Imperial Cancer Research Fund, G Lab of Molecular Phrmacology and Drug Metabolism, Hugh Robson JOURNAL

Building, George Square, Edinburgh, EH8 9XD 2 (bases 1 to 1415)

Alternative splicing in the human cytochrome P450IIB6 gene Miles, J.S., McLaren, A.Q. and Wolf, C.R. AUTHORS REFERENCE

Nucleic Acids Res. 17 (20), 8241-8255 (1989) generates a high level of aberrant messages JOURNAL

90045947 MEDLINE

The sequence is a compilation of genomic and cDNA clones. **map: chromosomal location=19q12-13.2; COMMENT

Data kindly reviewed (13-NOV-1989) by Miles, J.S.

FEATURES


Location/Qualifiers


FIG.2B CONT.


```
1 gaatteegee etgeaceeat gacegeetee caceagggee eegeeetetg eeeettttgg
                                                                                                                                                                                                                                                   /note=exon 9", coding region"
                                                                                                                                                                                                                                                                316 t
          /organism="Homo sapiens"
                                   1, partial"
                                                                                                                                                                                                                                                                  328 g
                                                                                                                                                                         /note=exon
904..1091
                                                                                                                      /note=exon
585..761
                                                                                                                                                /note=exon
762..903
                                                                                                                                                                                                                              note=exon
                                                                                                                                                                                                                                        1234..1415
                                                                                                                                                                                                    note=exon
                                                                                                                                                                                                              1092..1233
                                       /note=exon
                                                                                            /note=exon
                                                                   /note=exon
                                                                                                     424..584
                                                  111..273
                                                                             274..423
1..1415
                                                                                                                                                                                                                                                                       341 a
                                                                                                                                                                                                                                           misc-feature
                                                                                                          misc-feature
                                                                               misc_feature
                                                                                                                                                                                                                 misc.feature
                                                                                                                                                                                       misc-feature
                                                                                                                                                             misc.feature
                                                                                                                                    misc.feature
                                                     misc-feature
                           misc_feature
      source
                                                                                                                                                                                                                                                                        BASE COUNT
                                                                                                                                                                                                                                                                                      ORIGIN
```


FIG.2B CONT.

14/59












SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)







20/59











SUBSTITUTE SHEET (RULE 26)




CYP2A6 Antisense Knockdown in HepG2 Cells




Oligodeoxynucleotide Treatment


FIG.12




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)

Indole

35/59

FIG.23A

Chomone

3-Isochromanone

Dihydrocoumarin

36/59

Pilocarpine

Nicotine

$$\begin{array}{c|c} \text{CI} & \text{CI} \\ \text{H}_2\text{N} & \text{CH}_2 & \text{NH}_2 \end{array}$$

4,4'-Methylene bis[2-chloroaniline

6-Aminochrysene

 α -Naphthoflavone

FIG.23B

37/59

About 80% activity left at 0.05 mM concentration

70% inhibition at 0.5 mM concentration

$$S \longrightarrow CH_3$$
 [(CH₃)₂N]₃P(O) Hexamethylphosphoramide SM-12502 (CH₃)₂NNO

N-Nitrosodimethylamine

FIG.23C

<	(
7	ムケ
(ַכ
Ĺ	Ī

The SAS System
Experiment BC1; Pharmacokinetics of nicotine
Revised analysis of kinetics based on re-assays
Does treatment affect AUC?

Compound assayed=COTININE

	00	. • •	
۵۲ ۲۰	0.0397	AUC Mean 90876.07	Pr > F 0.0294 0.7690
מין כא	4.66		F Value 5.43 0.09
Mean	Square 151124745 324049670	Root MSE 18001.38	Mean Square 1758023983 30588081
Jo mus	Squares 10578731978 1944298022 12523030000	C.V. 19.80871	Type I SS 10548143898 30588081
AUC	DF 7 6 13	R-Square 0.844742	DF 6 1
Variable:	Total		
Dependent Variable:	Source Model Error		Source SUBJ TREATMNT

38/59

Least Squares Means

AUC	LSMEAN	92354.2010	7000 7000	111.11.100
THE STATE OF THE S	INEGILIA	Motbovsalen10-50		Placebo

\mathbf{B}
4
\sim
۲۲.
$\underline{\underline{\circ}}$
正


The SAS System
Experiment BC1; Pharmacokinetics of nicotine
Revised analysis of kinetics based on re-assays

	1 1 1 1 1 1		0.0317	AUC Mean 7165.426	Pr > F 0.1422 0.0038
		:	F. Value 5.14		F Value 2.52 20.86
ect AUC?	VICOTINE	Mean	Square 7839927.55 1523942.34	Root MSE 1234.481	Mean Square 3847592.43 31793938.32
Does treatment affect AUC?	Compound assayed=NICOTINE	Sum of	Squares 54879492.87 9143654.02 64023146.88	C.V. 17.22829	Type I SS 23085554.55 31793938.32
7.70	Com	AUC	DF 7 6 6 13	R-Square 0.857182	DF 6 1
אַע	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Dependent Variable:	Total		
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Dependent	Source Model Error Corrected		Source SUBJ TREATMNT


39/59


Least Squares Means

AUC	8672.40779
LSMEAN	5658.44323
TREATMNT	Methoxsalen10-50 Placebo




Plasma concentration







SUBSTITUTE SHEET (RULE 26)

CYP2A6 Inhibition --- Placebo Subjective Rating of Current Nausea (n=7) Test Cycle Number FIG.28A 10 Mean Sympton Score







47/59

-	% Inhibition at 150 uM	85 +/- 11 (SD, n=31)									(05=11,05) 01 -1+ 02) 3 +/- 11 (3D, 11=3U)
	% Inhibition at 100 uM	90 (n=1) 60 (n=3)	70 (n=3) 20 (n=3)	25 (n+1	1		/0 (n=3)		10 (n=1)	30 (n=1)		
etabolism by various Compounds	% Inhibition at 10 uM	65 (n=1) 40 (n=1)	20 (n=1) 10 (n=1)				30 (n=1)			20 (n=1)		-
ne Metabolism by	꼬	2 uM (n+4) 2.5 uM (n=1)	15 uM' >100 uM'	200 nM	14.5 uM (n=1)	0.1 uM	4.3 uM (n=1)	0.02 uM (n=1)	.100 uM*			
Inhibition of Nicotine to Cotinine M	Inhibitor	coumarin 7-melhoxycoumarin	7-methylcoumarin 7-ethoxycoumarin	7-hydroxycoumarin	diethyldithiocarbamic acid	pilocarpine	naringenin	methoxsalen	naringin	bupropion	orphenadrine	troleandomycin

all nicotine concentrations were at the Km value for cotinine formation in their respective livers • estimated from screening studies with 10 and 100 uM inhibitor concentrations

FIG.30A

48/59

Monkey liver 1.69 uM 24.1 uM 0.9 uM 0.29 uM 100.1 uM Human liver

Ki Values for the Inhibition of the CYP2A6 Substrate Coumarin to 7-Hydroxycoumarin Metabolism by various compound

FIG.30B

0.9 uM

pilocarpine

Inhibitor


methoxsalen

nicotine


Effect of Various Compounds on Cotinine Formation % control cotinine formation


Inhibitor	10 uM	100 uM
coumarin	35	10
naringenin	70	30
7-methylcoumarin	80	30
7-methoxycoumarin	. 60	40
bupropion	80	70
7-ethoxycoumarin	90	80

FIG.30C



SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)

DGELPESI.OGCOG







SUBSTITUTE SHEET (RULE 26)



SUBSTITUTE SHEET (RULE 26)







SUBSTITUTE SHEET (RULE 26)

OSELLELL COOSS

Comparsison Between Morning and Afternoon Testing Sessions





Metabolism of Nicotine over one hour Mean and s.d., seven subjects

30

--- Methoxsalen, AUC= 15 Elapsed time, hours 0.5

Placebo vs Methoxsalen AUC to 1 hour: F(1,6)=8.07,p=0.0295 FIG.38 --- Placebo, AUC= 12

10-

OR Plasma concentration